Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) traded down 3.5% on Wednesday . The stock traded as low as $2.95 and last traded at $3.06. 2,110 shares traded hands during trading, a decline of 67% from the average session volume of 6,308 shares. The stock had previously closed at $3.17.
Analyst Upgrades and Downgrades
Several equities analysts have commented on EPRX shares. Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, November 14th. They issued a "buy" rating and a $9.00 price target on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, November 14th.
Read Our Latest Report on EPRX
Eupraxia Pharmaceuticals Stock Performance
The business has a 50-day moving average of $3.19 and a 200-day moving average of $2.83. The stock has a market capitalization of $83.48 million and a price-to-earnings ratio of -4.25.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter. On average, research analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.67 earnings per share for the current fiscal year.
Eupraxia Pharmaceuticals Company Profile
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
